Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:33:38.182Z.
Consensus retrieved: 2026-10-06T15:14:38.203Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:33:38.182Z.
Quote observation: 2026-10-06T16:49:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ac2c7a41ad5640622b079511a65f3d79aa9aa97fd30809e3a9f0c7038551df0a
Forward PE Ratio (N/A) = Dated Quote Price ($6.00) / Consensus Forward EPS ($-7.27)
FORWARD PE RATIO
N/A
P3 Health Partners Inc.
Market Cap
$19.67M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| P3 Health Partners Inc. (PIII) | $19.67M | N/A |
| NextCure, Inc. (NXTC)vs › | $19.51M | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.43M | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.67M | N/A |
| Modular Medical, Inc. (MODD)vs › | $21.03M | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $21.24M | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.87M | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.58M | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.05M | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.11M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.00, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-7.27 | $-7.46 – $-7.08 | 1 | n/m |
| 2027-12-31 | $-10.16 | $-10.43 – $-9.90 | 1 | n/m |
| 2028-12-31 | $-5.27 | $-5.41 – $-5.13 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
